NCT06082635View on ClinicalTrials.gov

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

December 14, 2023

Primary Completion Date

April 30, 2026

Study Completion Date

November 30, 2028

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

TGRX-326

Subjects will be treated with the investigational drug TGRX-326 at 60 mg once a day in 28-day cycles

DRUG

Crizotinib

Subjects will be treated with the control drug crizotinib at 250 mg twice a day in 28-day cycles

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
collaborator

Sun Yat-sen University

OTHER

lead

Shenzhen TargetRx, Inc.

INDUSTRY